Fate Therapeutics Operating Income Over Time
| FATE Stock | USD 1.16 0.07 5.69% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Fate Therapeutics Performance and Fate Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Fate diversify its offerings? Factors like these will boost the valuation of Fate Therapeutics. Market participants price Fate higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fate Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.32) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fate Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Fate Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | (1.3 M) | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.8 M) | (18.7 M) | (14 M) | (26.7 M) | (25.1 M) | (22.6 M) | (21.5 M) |
| BLRX | (33.3 M) | (16.4 M) | (21.1 M) | (17 M) | (17.3 M) | (16.2 M) | (16.5 M) | (25.2 M) | (25.6 M) | (28.1 M) | (22.9 M) | (24.8 M) | (29.2 M) | (49.7 M) | (20.4 M) | (18.4 M) | (19.3 M) |
| THAR | (994.5 K) | (994.5 K) | (994.5 K) | (994.5 K) | (994.5 K) | (994.5 K) | (994.5 K) | (994.5 K) | (994.5 K) | (994.5 K) | (1.5 M) | (3.2 M) | (6.9 M) | (9.5 M) | (12.4 M) | (11.2 M) | (10.6 M) |
| APLM | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (40.6 M) | (50.9 M) | (45.1 M) | (54 M) | (42.1 M) | (37.9 M) | (39.8 M) |
| AIMD | (800 K) | (1.1 M) | (554.6 K) | (566.2 K) | (622.6 K) | (519.8 K) | (667.1 K) | (579.8 K) | (1.3 M) | (1.6 M) | (1.4 M) | (3.9 M) | (14 M) | (13.2 M) | (13.8 M) | (12.5 M) | (11.8 M) |
| OSRH | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (3.3 K) | (35.4 K) | (1.8 M) | (3.5 M) | (3.2 M) | (3 M) |
| LPCN | (5.2 K) | (5.2 K) | (76.7 K) | (8.8 M) | (20.5 M) | (18.4 M) | (18.5 M) | (21.2 M) | (11.3 M) | (12.9 M) | (18 M) | 3.1 M | (12.1 M) | (17.9 M) | (1.2 M) | (1 M) | (1.1 M) |
| ADTX | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (5.6 M) | (5.9 M) | (8.9 M) | (41.9 M) | (25.5 M) | (26.1 M) | (27.9 M) | (25.1 M) | (26.3 M) |
| ICU | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (4.4 M) | (11.6 M) | (14.2 M) | (17.8 M) | (16.1 M) | (16.9 M) |
Fate Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Operating Income description
Operating Income is the amount of profit realized from Fate Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Fate Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Fate Therapeutics | FATE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 12278 Scripps Summit |
| Exchange | NASDAQ Exchange |
USD 1.16
Check out Fate Therapeutics Performance and Fate Therapeutics Correlation. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Fate Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.